key: cord-0956824-d4mog1f4
authors: Majadas, Susan; Pérez, Javier; Casado‐Espada, Nerea M.; Zambrana, Antonio; Bullón, Alberto; Roncero, Carlos
title: A case with psychotic disorder as a clinical presentation of COVID‐19
date: 2020-07-08
journal: Psychiatry Clin Neurosci
DOI: 10.1111/pcn.13107
sha: fed8b2d9de51be62913c3ef00894d93286b33177
doc_id: 956824
cord_uid: d4mog1f4

nan

In the COVID-19 pandemic reactive psychiatric symptoms and exacerbation of pre-existing psychiatric conditions have been widely described as secondary effects of social isolation, consequence of the obliged quarantine, fear of the infection or a complicated grief for the unexpected loss of beloved people (1, 2) . Nevertheless the scientific community working directly with COVID-19 patients is facing complex neuropsychiatric syndromes, including first onset of psychosis, that seem to be directly related to brain damage in the context of the COVID-19 (3). This is the first report, to the best of our knowledge, describing of a non-reactive psychosis break directly COVID-19-related in a naïve psychiatric patient. A 63-year-old male, with no previous psychiatric history, was first admitted in hospital presenting with bilateral pneumonia and positive PCR-COVID-19 test (March 30th 2020), being diagnosed with COVID-19. He also presented with a delirium during the hospitalization (Table 1) , that improved in parallel to the respiratory disorder leading to patient's discharge (April 8th 2020). Ambulatory treatment with risperidone 2 mg per day was maintained, but bizarre delusions and incoherent thought and speech didn't disappear even after antipsychotic treatment adjustment, so the patient's was referred to hospital again (April 15th 2020).

At this second in-hospital admission a new PCR-COVID-19 test was performed with positive result. Respiratory evaluation was normal. An elevation of D-dimer level was detected in the blood test and a CT pulmonary angiography showed a low risk pulmonary thromboembolism (PTE), which was determined to be related to COVID-19 and treated with anticoagulants. In the first psychiatric evaluation the patient referred thoughts of changes occurred in his body, including the absence of anus, so he had decided not to eat anything to avoid exploding. At first fluctuant attention and orientation to time and place were observed, but no other common features of a delirium were present. A cranial MRI with contrast enhancement showed no significant findings. Finally a diagnoses of Psychotic Disorder Due to Another Medical Condition (COVID-19) was made following DSM-5 criteria. During the case follow-up by the Liaison Psychiatry department the delusions content changed -the patient related that most of his relatives had died-and auditory verbal hallucinations appeared. Risperidone was titrated in the following days from 2.5 mg per day up to 6 mg per day. On April 30 th 2020 the patient was mostly recovered, with absence of delusions and hallucinations and critical thought about the psychotic symptoms presented, so he was discharged and referred to his outpatient Mental Health Unit for further follow-up.

This case report shows the possibility of a first psychosis break as a direct (non-reactive) COVID-19-related syndrome. The hypothesis of a link between this and an increased immunologic response of the body to the virus affecting the brain may be extrapolated from previous reports linking other respiratory virus infections and the occurrence of psychosis (4). Psychosis post NIH1 virus infection in children was associated to viral induced brain-reactive autoantibodies production (5). Severance et al (2011) (6) found a highest level of immunoglobulins G against four different human coronavirus strains in adults diagnosed with psychosis versus controls. An interesting aspect of the case reported is the concomitant occurrence of the psychotic episode and the PTE, since both thrombotic phenomena and neuropsychiatric symptoms have been recently described as a potential sequelae of the inflammatory storm and the immunoreactivity associated to COVID-19 (7, 8) .

The hypothesis of the occurrence of psychosis as an adverse reaction to some of the treatments used for the COVID-19, such as hydroxychloroquine or corticosteroids, was also considered but found improbable, since no temporary correlation existed between these treatments administration and the onset of psychosis, with more than a two week-period between both events. In fact in a review of adverse reactions reported in chloroquine treated patients between 2012 and 2019 (9) no statistically significant reporting of psychosis was found.

Overall, the current case report illustrates the possibility of a psychosis break as one of the COVID-19 clinical presentations. Though its underlying mechanisms are still unknown, the existing evidence from scientific literature guides to a potential participation of inflammatory and auto-immunologic phenomena triggered as response to the coronavirus infection. More investigation on the basis of neuropsychiatric complications of the COVID-19, such us onset of psychosis, is needed to ratify or not this hypothesis.

The patient gave the informed consent and his anonymity was preserved. This report as well confirms the new clinical and managing challenges for the professionals and mental health network (10). 

Mental health during and after the COVID-19 emergency in Italy

Reactive Psychoses in the Context of the COVID-19 Pandemic: Clinical Perspectives From a Case Series

Clinical and Epidemiological Characteristics of 1,420 European Patients with mild-to-moderate Coronavirus Disease

COVID-19 and Psychosis: Is There a Link?

Childhood psychosis after H1N1 influenza

Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms

Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far? Acta Haematol

Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms

Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. Biosci Trends

Dr. Susana Majadas: Dr Javier Pérez, Dr Nerea Casado-Espada, Dr Zambrana and Dr Alberto Bullón no conflicts of interest to declare. Dr Carlos Roncero has received fees to give lectures for Janssen-Cilag, Indivior, Lundbeck, Otsuka, Servier, GSK, Astra, Gilead, MSD, Sanofi, Exceltis, Abbvie, Takeda Rubio and Casein. He has received financial compensation for his participation as consultant or a board member of Lundbeck, Gilead, MSD, Mundipharm, INDIVIOR, Exceltis, Martindale, Camurus, Gebro and Abbive board. He has carried out the PROTEUS project, which was funded by a grant from Reckitt-Benckisert/Indivior and the COSTEDOPIA project, which was funded by INDIVIOR. He received two medical education grants by Gilead.No funding was received for this work.This article is protected by copyright. All rights reserved.